Actavis’ Launch Of Pulmicort Respules Generic Halted By Court
This article was originally published in The Pink Sheet Daily
Executive Summary
One day after declaring one Pulmicort patent invalid and another not infringed, a New Jersey federal judge granted AstraZeneca’s bid to temporarily block Actavis and other ANDA filers from launching and distributing their budesonide generics.
You may also be interested in...
Protonix Settlement Leaves Question Of How Jury Would Assess At-Risk Launch Damages
Teva and India’s Sun Pharma are to pay $2.15 billion for their at-risk launch in the U.S. of generic versions of Pfizer’s Protonix; Pfizer says figure represents lost profits and lost royalties from the three years the product faced premature generic competition.
Protonix Settlement Leaves Question Of How Jury Would Assess At-Risk Launch Damages
Teva and Sun are to pay $2.15 billion for their at-risk launch of generic versions of Pfizer’s Protonix; Pfizer says figure represents lost profits and lost royalties from the three years the product faced premature generic competition.
Actavis’ Pulmicort Respules Generics Race Out The Door Before “Short Injunction”
The company is barred from further distributing its budesonide inhalation suspension until April 12; the generic launched April 1 following a patent victory over AstraZeneca, but a New Jersey federal judge said a “limited temporary injunction” was warranted to give the innovator time to seek appellate relief.